Mirati Therapeutics provides update on the phase III SAPPHIRE study evaluating sitravatinib in combination with Opdivo in NSCLC.
Mirati Therapeutics, Inc. announced that the SAPPHIRE study did not meet its primary endpoint of overall survival at the final analysis
SAPPHIRE is a Phase III study evaluating sitravatinib in combination with nivolumab (Opdivo) versus docetaxel in patients with second or third line advanced non-squamous non-small cell lung cancer (NSQ-NSCLC) who progressed on prior therapy with chemotherapy and immune checkpoint inhibitor therapy. The company plans to disclose the study data at a future date.
Principal Investigators will be given the option to continue therapy for patients who are experiencing clinical benefit and would like to remain on treatment.
Related news and insights
Zai Lab Limited and Novocure are presenting positive results from the phase III LUNAR clinical trial evaluating the use of Tumor Treating Fields (TTFields) therapy together with standard therapies for the treatment of non-small cell lung cancer (NSCLC) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Pfizer Inc. announced the first detailed results from the Phase II PHAROS study, which is evaluating the efficacy and safety of Braftovi (encorafenib) given in combination with Mektovi(binimetinib) to patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC)
Updated results from the TROPION-Lung02 Phase Ib trial showed that, with additional enrolment and follow-up from the initial presentation, datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum-based chemotherapy demonstrated promising clinical activity and no new safety signals in both previously untreated or pretreated patients with advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGAs)